These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37684512)

  • 1. Synergistic antitumor efficacy of gemcitabine and cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via Sp1-SAT1-polyamine metabolism pathway.
    Wei W; Lu Y; Hu Q; Yin J; Wang Y; Zhang H; Zhao Q; Liu L
    Cell Oncol (Dordr); 2024 Feb; 47(1):321-341. PubMed ID: 37684512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Ferroptosis Signature in Overall Survival and Chemotherapy of Pancreatic Adenocarcinoma.
    Wei W; Hu Q; Li W; Li M; Dong S; Peng Y; Yin J; Lu Y; Liu L; Zhao Q
    DNA Cell Biol; 2022 Feb; 41(2):116-127. PubMed ID: 34898275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses.
    Ou Y; Wang SJ; Li D; Chu B; Gu W
    Proc Natl Acad Sci U S A; 2016 Nov; 113(44):E6806-E6812. PubMed ID: 27698118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism.
    Du J; Wang X; Li Y; Ren X; Zhou Y; Hu W; Zhou C; Jing Q; Yang C; Wang L; Li H; Fang L; Zhou Y; Tong X; Wang Y
    Cell Death Dis; 2021 Jul; 12(7):705. PubMed ID: 34262021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine Resistant Pancreatic Cancer.
    Gitto SB; Pandey V; Oyer JL; Copik AJ; Hogan FC; Phanstiel O; Altomare DA
    Mol Pharm; 2018 Feb; 15(2):369-376. PubMed ID: 29299930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs.
    Qi R; Bai Y; Li K; Liu N; Xu Y; Dal E; Wang Y; Lin R; Wang H; Liu Z; Li X; Wang X; Shi B
    Drug Resist Updat; 2023 May; 68():100960. PubMed ID: 37003125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MUC1-HIF-1α signaling axis regulates pancreatic cancer pathogenesis through polyamine metabolism remodeling.
    Murthy D; Attri KS; Suresh V; Rajacharya GH; Valenzuela CA; Thakur R; Zhao J; Shukla SK; Chaika NV; LaBreck D; Rao CV; Hollingsworth MA; Mehla K; Singh PK
    Proc Natl Acad Sci U S A; 2024 Apr; 121(14):e2315509121. PubMed ID: 38547055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma.
    Zhu YX; Li CH; Li G; Feng H; Xia T; Wong CH; Fung FKC; Tong JH; To KF; Chen R; Chen Y
    Cell Mol Gastroenterol Hepatol; 2020; 10(4):811-828. PubMed ID: 32615164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.
    Cai B; An Y; Lv N; Chen J; Tu M; Sun J; Wu P; Wei J; Jiang K; Miao Y
    Oncol Rep; 2013 May; 29(5):1769-76. PubMed ID: 23440261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma.
    Shang M; Weng L; Xu G; Wu S; Liu B; Yin X; Mao A; Zou X; Wang Z
    J Cell Physiol; 2021 Oct; 236(10):6868-6883. PubMed ID: 33629745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
    She C; Wu C; Guo W; Xie Y; Li S; Liu W; Xu C; Li H; Cao P; Yang Y; Wang X; Chang A; Feng Y; Hao J
    J Exp Clin Cancer Res; 2023 Sep; 42(1):238. PubMed ID: 37697370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma.
    Fu D; Yan J; Zhang Z; Liu Y; Ma X; Ding J; Yang S; Zhao R; Chang A; Gao C; Liu J; Zhao T; Wang X; Huang C; Gao S; Ma Y; Tang B; Feng Y; Wang H; Hao J
    Cancer Biol Med; 2023 Jun; 20(8):599-626. PubMed ID: 37381714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
    Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
    Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
    Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer.
    Zhang X; Zhao P; Wang C; Xin B
    Biochem Biophys Res Commun; 2019 Mar; 510(4):508-514. PubMed ID: 30737032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Ma L; Fan Z; Du G; Wang H
    Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.
    Tu Q; Liu X; Yao X; Li R; Liu G; Jiang H; Li K; Chen Q; Huang X; Chang Q; Xu G; Zhu H; Shi P; Zhao B
    J Exp Clin Cancer Res; 2022 Sep; 41(1):274. PubMed ID: 36109793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
    Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.